HKU Data Repository
Download file
Download file
2 files

Supporting data for Tumor intrinsic pathways dictate the immune landscape and responses to immune checkpoint inhibitors in liver cancer

posted on 2022-12-14, 02:29 authored by Wai Hin YuenWai Hin Yuen

Immune checkpoint inhibitors (ICIs) have reached unprecedented clinical success in multiple cancer types including hepatocellular carcinoma (HCC). However, there is still a signficant proportion of HCC patients not responding to ICIs. My studies revealed that tumor-intrinsic oncogenic pathways could determine the intratumoral immune composition and thus the response to ICIs. By studying anti-PD-1-resistant mouse HCC model, I identified another immune checkpoint, TIGIT, being upregulated after anti-PD-1 treatment. TIGIT upregulation conferred anti-PD-1 resistance. Co-blockade of PD-1 and TIGIT could overcome this resistance.

Quantitaive real-time polymerase chain reaction (qRT-PCR) was used to examine key HCC genes expressed in mouse HCC tumors, proinflammatory chemokines upregulated in immune-inflamed tumors, and PVR family gene expression (ligands of TIGIT) in HCC cell lines.


Usage metrics

    Research Postgraduates